Kite Pharma is flying high with the addition of ... registered a 1% year-over-year drop in sales and its counterpart Tecartus gained just 2%. At the time, Gilead linked the stagnation to ...

The FDA has approved Kite Pharma's Tecartus as a treatment for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL), making CAR-T therapy an option for an ...

Gilead’s $11.9 billion purchase of Kite Pharma in 2017 didn’t follow the ... Late last week, the FDA approved Kite's Tecartus (brexucabtagene autoleucel; formerly KTE-X19) as a treatment ...

Lupus involves unpredictable symptom flares and potential changes in brain chemistry that may increase your risk of experiencing depression and anxiety. Lupus is a chronic (long-term) autoimmune ...

Hypoglycemia (low blood sugar) is not a formal symptom of lupus, but it may develop from related factors like medication use, other autoimmune processes in the body, and hormonal changes.

The past two years have been punishing for the biotech and pharma space. As Wall Street chased the artificial-intelligence boom, drugmakers were left behind, with pharma stocks trading at a ...

Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving ...

Gilead Sciences boasts four approved cancer types between its two CD19 CAR-T products, Yescarta and Tecartus, one being an acute lymphoblastic leukemia indication that Breyanzi doesn’t have.

New Delhi, Feb. 07, 2025 (GLOBE NEWSWIRE) -- The global CAR T-cell therapy market valuation is poised to reach US$ 22.2 billion by 2032, with a CAGR of 30% during the forecast period from 2024 to ...

Living with lupus can significantly affect your mental health. This January we are honoring Mental Wellness Month by exploring the intersection of lupus and mental health with a four-part series of ...

Brexucabtagene autoleucel (Tecartus) – FDA approved on October 1, 2021, for adult r/r B-ALL. Gilead’s (GILD) Tecartus is a CD19 directed CAR-T just like AUCATZYL, however it has a poor tox ...

Story Jan. 10 - Shoreline Biosciences: The cell therapy biotech plans to let go of an undisclosed number of employees tied to a project with Gilead Sciences’ Kite Pharma. Story Jan. 9 - IGM ...